ABSTRACT
Cardiovascular diseases are possible complications of antineoplastic treatment and may lead to premature morbidity and mortality among cancer survivors. A symptom-based follow-up is ineffective, and there are growing evidences that early detection of myocardial damage in patients treated with antineoplastic drugs is the key point to prevent the occurrence of damage and improve the prognosis of these patients. Different techniques have been proposed to monitor cardiac function in oncologic patients such as cardiac imaging (echocardiography, nuclear imaging, and cardiac magnetic resonance) and biomarkers (troponin and natriuretic peptides). The European Association of Cardiovascular Imaging/American Society of Echocardiography consensus document encourages an integrated approach to early detect cardiotoxicity.
PMID:32566460 | PMC:PMC7293866 | DOI:10.4103/jcecho.jcecho_2_19
05:05
PubMed articles on: Cancer & VTE/PE
High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma
Mahajan A, et al. Leuk Lymphoma 2020.
Comments
Post a Comment
اكتب تعليق حول الموضوع